Spotlight on Lanreotide Autogel® in Acromegaly

被引：0
|
作者：
Jamie D. Croxtall
Lesley J. Scott
机构：
[1] Wolters Kluwer Health ¦ Adis,
[2] Wolters Kluwer Health,undefined
来源：
BioDrugs | 2008年 / 22卷
关键词：
Growth Hormone; Acromegaly; Growth Hormone Level; Lanreotide; Somatuline;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Lanreotide Autogel® (ATG) [Somatuline® Depot]1 is a novel, long-acting preparation of the somatostatin analog lanreotide acetate that acts via somatostatin receptors to reduce both growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels. It is indicated for the management of acromegaly and, relative to most other licensed agents, it has a favorable pharmacokinetic profile that permits administration once every 28–42 days.
引用
收藏
页码：275 / 277
页数：2
相关论文
共 50 条
  • [31] Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study
    Philippe J. Caron
    John S. Bevan
    Stephan Petersenn
    Aude Houchard
    Caroline Sert
    Susan M. Webb
    Pituitary, 2016, 19 : 149 - 157
  • [32] Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study
    Stephan Petersenn
    Aude Houchard
    Caroline Sert
    Philippe J. Caron
    Pituitary, 2020, 23 : 171 - 181
  • [33] Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study
    Caron, Philippe J.
    Bevan, John S.
    Petersenn, Stephan
    Houchard, Aude
    Sert, Caroline
    Webb, Susan M.
    PITUITARY, 2016, 19 (02) : 149 - 157
  • [34] Clinical experience with lanreotide for the treatment of acromegaly
    Roemmler, Josefine
    Schopohl, Jochen
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2012, 7 (02) : 139 - 149
  • [35] Population Pharmacokinetic Analysis of Lanreotide Autogel® in Healthy SubjectsEvidence for Injection Interval of Up to 2 Months
    Iñaki F. Trocóniz
    Josep-María Cendrós
    Concepción Peraire
    Joaquim Ramis
    Maria J. Garrido
    Paolo F. Boscani
    Rosendo Obach
    Clinical Pharmacokinetics, 2009, 48 : 51 - 62
  • [36] Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN)
    Zhenmei An
    Ting Lei
    Lian Duan
    Pei Hu
    Zhongping Gou
    Lihui Zhang
    Lucie Durand-Gasselin
    Nan Wang
    Yan Wang
    Feng Gu
    BMC Endocrine Disorders, 20
  • [37] Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naive patients with acromegaly: data from the PRIMARYS study
    Caron, Philippe J.
    Petersenn, Stephan
    Houchard, Aude
    Sert, Caroline
    Bevan, John S.
    CLINICAL ENDOCRINOLOGY, 2017, 86 (04) : 541 - 551
  • [38] Primary treatment of acromegaly with high-dose lanreotide: A case series
    Wuster C.
    Both S.
    Cordes U.
    Omran W.
    Reisch R.
    Journal of Medical Case Reports, 4 (1)
  • [39] Slow-release lanreotide treatment in acromegaly: Effects on quality of life
    Sonino, N
    Scarpa, E
    Paoletta, A
    Fallo, F
    Boscaro, M
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 1999, 68 (03) : 165 - 167
  • [40] Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naive to somatostatin-receptor ligands: analysis of three multicenter clinical trials
    Alquraini, Hussain
    Schneider, Maria del Pilar
    Mirakhur, Beloo
    Barkan, Ariel
    PITUITARY, 2018, 21 (03) : 283 - 289
12345